UK markets closed
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • FTSE 250

    22,734.13
    +125.33 (+0.55%)
     
  • AIM

    1,249.65
    +3.03 (+0.24%)
     
  • GBP/EUR

    1.1652
    +0.0013 (+0.11%)
     
  • GBP/USD

    1.4109
    -0.0067 (-0.48%)
     
  • BTC-GBP

    27,670.47
    +2,163.34 (+8.48%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • DOW

    34,479.60
    +13.40 (+0.04%)
     
  • CRUDE OIL

    70.78
    -0.13 (-0.18%)
     
  • GOLD FUTURES

    1,879.50
    -0.10 (-0.01%)
     
  • NIKKEI 225

    28,948.73
    -9.87 (-0.03%)
     
  • HANG SENG

    28,842.13
    +103.23 (+0.36%)
     
  • DAX

    15,693.27
    +122.07 (+0.78%)
     
  • CAC 40

    6,600.66
    +54.17 (+0.83%)
     

Global Oligonucleotide Synthesis Markets Report 2021-2026 - Increasing Use of Synthesized Oligos in Therapeutic Applications with Growing Focus on Personalized Medicine

·3-min read

Dublin, May 20, 2021 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic), End User (Hospital, Pharma, CROs) - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

The global oligonucleotide synthesis market is projected to reach USD 14.1 billion by 2026 from USD 6.3 billion in 2021, at a CAGR of 17.6% during the forecast period.

The major factors driving the growth of this market include the increasing use of synthesized oligos in therapeutic applications, increasing government funding, and the growing focus on personalized medicine.

"By synthesized oligos product segment, the primers segment accounted for the fastest-growing segment of the oligonucleotide synthesis market"

Based on product, the oligonucleotide synthesis market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides, reagents, and equipment. By product, the synthesized oligonucleotides market is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos. In 2020, the primers segment accounted for the fastest growing segment of this market, as they are used in various applications such as PCR, sequencing, gene synthesis, and cloning applications, among others.

"By therapeutic application, the antisense oligonucleotide-based therapies segment accounted for the largest share of the oligonucleotide synthesis market"

Based on application, the oligonucleotide synthesis market is segmented into therapeutic, research, and diagnostic applications. The therapeutic application segment is further segmented into Antisense oligonucleotide-based therapies, siRNAi oligonucleotide-based therapies, and CpG oligonucleotide-based therapies. IN 2020, antisense oligos accounted for the largest share of this segment as they form the basis of many therapies that are currently in clinical trials, thus boosting segment growth.

"Asia Pacific: The fastest-growing region in the oligonucleotide synthesis market."

The oligonucleotide synthesis market in the Asia Pacific region is projected to register the highest growth during the forecast period. Factors such as growing R&D funding, rising product availability, lower outsourcing costs, increasing research activities, increasing applications of oligos in molecular diagnostics & therapeutics, and the rising awareness of oligonucleotides are expected to drive market growth.

"North America: the largest share of the oligonucleotide synthesis market"

North America accounted for the largest market share. The large share of this region can be attributed to the increasing R&D in life sciences, rising focus on improving the safety & quality of healthcare, rising demand for high-quality research tools for data reproducibility, and increasing focus on developing personalized therapeutics. The presence of many global players in this region is another key factor contributing to the large share of this market segment.

Premium Insights

  • Oligonucleotide Synthesis Market Overview: Increasing Use of Synthesized Oligos in Therapeutic Applications is a Key Factor Expected to Drive Market Growth

  • Asia-Pacific: Oligonucleotide Synthesis Market, by Application & Country (2020) - Therapeutic Applications Accounted for the Largest Share of the Asia-Pacific Market in 2020

  • Oligonucleotide Synthesis Market for Therapeutic Applications, by Type: Antisense Oligonucleotide-Based Therapies Segment is Projected to Witness the Highest Growth During the Forecast Period

Market Dynamics

Drivers

  • The Increasing Use of Synthesized Oligos in Therapeutic Applications

  • Increasing Government Investments for Synthetic Biology and Genome Projects

  • Growing Focus on Personalized Medicine

Restraints

  • Complexities Associated with Therapeutic Oligos

Opportunities

  • Key Players in Emerging Economies

Challenges

  • Delivery of Oligonucleotide Drugs to Specific Targets

Impact of COVID-19 on the Oligonucleotide Synthesis Market

Supply Chain Analysis

  • Key Influencers

Porter's Five Forces Analysis

Value Chain Analysis

Ecosystem Analysis of the Oligonucleotide Synthesis Market

Technological Analysis

  • Solid-Phase Synthesis

  • Liquid-Phase Synthesis

Regulatory Analysis

  • Government Regulations for Oligonucleotide-Based Drugs:

  • Government Regulations for Synthesized Oligonucleotides: Good Manufacturing Practice (Gmp)

  • Iso 13485

  • Ivd & Asr

Patent Analysis

Trade Data

Pricing Analysis

Company Profiles

Major Players

  • Danaher Corporation

  • Thermo Fisher Scientific, Inc.

  • Merck Kgaa

  • Eurofins Scientific

  • Lgc Limited

  • Maravai Lifesciences

  • Agilent Technologies, Inc.

  • Kaneka Corporation

  • Biolegio B.V.

  • Biolytic Lab Performance Inc.

  • Microsynth Ag

Other Players

  • Adtbio Ltd.

  • Twist Bioscience Corporation

  • Eton Bioscience, Inc.

  • Csbio

  • Tag Copenhagen A/S

Therapeutic Players

  • Biogen Inc.

  • Sarepta Therapeutics, Inc.

  • Ionis Pharmaceuticals, Inc.

  • Alnylam Pharmaceuticals, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/4g486n

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900